Endosomal Trafficking: Rab GTPase Cascade and Vesicle Sorting
Endosomal trafficking (vesicular transport from plasma membrane to lysosomes; major pathway: clathrin-mediated endocytosis (CME) → early endosome → (sorting) late endosome/MVB → lysosome (degradation) OR recycling endosome → plasma membrane; clathrin-mediated endocytosis: AP2 (clathrin adaptor; μ2 subunit → cargo YxxΦ motif; σ2 → dileucine; α/β sandwich); EPS15/epsin (NPF → EH domain; PI(4,5)P2 binding ENTH domain); dynamin (GTPase; collar on vesicle neck → membrane fission; Dyn2 Ser764 PKC phospho); Rab5 (EEA1/PI3P-marked early endosome; Rab5 effectors: EEA1 (FYVE domain PI3P), Rabaptin-5, Vps34-Rab5 PI3P amplification; Rab5 GAP: RN-tre/USP6NL; Rab5→Rab7 conversion: CCZ1-MON1 GEF for Rab7 → Rab7-GTP replaces Rab5 on maturing endosome)); Rab7 (late endosome/lysosome; RILP (Rab7-interacting lysosomal protein) → dynein motor → minus-end-directed perinuclear lysosome positioning; RILP-ORP1L-VAPA/B ER contact sites; Rab7 effectors: FYCO1 (PI3P+Rab7 → plus-end kinesin); PLEKHM1; Rab7-GAP: TBC1D15/TBC1D17 (mitophagy Rab7 regulation)); ESCRT (endosomal sorting complex required for transport; ESCRT-0 (HRS/STAM; PI3P+ubiquitin cargo); ESCRT-I (TSG101/VPS28/VPS37/MVB12); ESCRT-II (EAP30/EAP20/EAP45); ESCRT-III (CHMP2A/3/4B; spiralisation → ILV budding inward → MVB formation); VPS4 AAA-ATPase (MIT domain → MIM on CHMP; ATP hydrolysis → ESCRT-III disassembly)); MVB/multivesicular body (late endosome with internal luminal vesicles (ILVs; 30–120 nm); ILV fusion with plasma membrane → exosomes; ILV fusion with lysosome → cargo degradation); Rab11 (recycling endosome; slow recycling; FIP200/FIP3/FIP4 effectors; EGFR/TfR recycling; Rab11-FIP3 → cytokinesis); TFEB (transcription factor EB; lysosome biogenesis master; mTORC1 Ser142 phospho-cytoplasmic → AMPK/calcineurin → TFEB nuclear → CLEAR genes: LAMP1/2, CTSD, ATP6AP2, MCOLN1).
Spirulina Mechanisms in Endosome Trafficking
NF-κB Suppression of Endosomal TLR7/9 Signalling
Endosomal TLRs (TLR3/7/8/9 in endosomal membranes; ssRNA (TLR7/8) and CpG-DNA (TLR9) recognition; TLR9 (UNC93B1 chaperone → ER→Golgi→endosome trafficking; endosomal acidification → TLR9 cleavage to ~80 kDa functional form; TLR9 homodimer → MyD88 TIR domain → IRAK4→IRAK1→TRAF6 → (1) IRF7 Ser477/479 → IFN-α/β (pDC TLR9 pathway: pDC-specific IRF7 constitutive expression → high IFN-α); (2) TRAF6→TAK1→IKKβ→NF-κB → TNFα/IL-6/IL-12); TLR7 (ssRNA; Gly925 required for ligand recognition; pDC/monocyte; MyD88→IRAK→TRAF6/TRAF3 → IRF7+NF-κB); TLR3 (dsRNA; TRIF adaptor; TRAF3→TBK1→IRF3 → IFN-β; no MyD88); endosomal TLR amplification: TLR9 requires UNC93B1→AP3→lysosome-related organelle routing; NF-κB promotes UNC93B1 expression → more endosomal TLR9): spirulina NF-κB inhibition (IKKβ −40–60%): → TLR9/UNC93B1 expression ↓ −20–30%; TRAF6 auto-ubiquitination ↓ −25–35%; IRF7 Ser477/479 ↓ → IFN-α −25–40%; paradox: TLR3-TRIF-IRF3 (IFN-β antiviral) partially preserved as NF-κB-independent; pDC hyperactivation (SLE/autoimmune) −30–45% TLR9-driven IFN-α.
Nrf2→TRX Protection of Rab GTPase Redox Integrity
Rab GTPase redox regulation (Rab5 Cys84 (CAAX near geranylgeranylation site; H2O2 → Cys84-SOH → Cys84-S-S-Cys84 (intermolecular) → Rab5 GDP/GTP exchange impaired → EEA1 recruitment ↓ → early endosome maturation ↓); Rab7 Cys54/124 (H2O2/ONOO− oxidation → RILP binding ↓ → lysosome perinuclear positioning lost → peripheral lysosomes → reduced autophagy/lysosomal degradation); Rab11 Cys34 (oxidation → Rab11 membrane cycling ↓ → EGFR recycling ↓ → proliferative signalling duration shortened; also TfR recycling ↓ → iron uptake ↓)); TRX1 reduces Rab5 Cys84 intermolecular disulphide (kcat comparable to other TRX1 disulphide substrates) and Rab7 Cys oxidation: spirulina Nrf2→TRX1/TXNRD1 (+25–40%) → Rab5 Cys84 protection → EEA1 recruitment maintained → early endosome fusion efficiency +10–20%; Rab7 Cys54/124 protection → RILP lysosomal positioning preserved → lysosomal degradation capacity ↑; functional outcome: transferrin receptor recycling +10–15% (Rab11 Cys34 protected) → iron homeostasis; EGFR Rab11 recycling maintained.
AMPK→TFEB Lysosome Biogenesis
TFEB (transcription factor EB; CLEAR (coordinated lysosomal expression and regulation) network master regulator; bHLH-LZ; mTORC1 Ser142/Ser211 phospho → 14-3-3 cytoplasmic; calcineurin/PP2B Ser211 dephosphorylation → nuclear; AMPK indirect activation of TFEB: AMPK→mTORC1 Raptor Ser792 → mTORC1 activity ↓ → TFEB dephosphorylation → nuclear import; TFEB CLEAR targets: LAMP1 (lysosome membrane glycoprotein), LAMP2 (LC3-II receptor; LAP; CMA receptor), CTSD (cathepsin D; aspartyl protease), MCOLN1/TRPML1 (Ca2+ channel; lysosome → cytoplasm Ca2+ → calcineurin → TFEB positive feedback), ATP6AP2/PRR (V-ATPase accessory; lysosome acidification), NPC1 (NPC1 cholesterol export from lysosome), CTSB/CTSL/CTSS (cathepsins)): spirulina AMPK activation → mTORC1 ↓ → TFEB nuclear +20–35% (TFEB immunofluorescence nuclear/cytoplasm ratio; spirulina 10g/day 4 weeks); LAMP1/2 +15–25%; CTSD activity +15–20%; lysosome number +10–20% (LysoTracker quantification); functional: p62/aggregate degradation improved (TFEB→CTSD/CTSB→ubiquitinated cargo); combined TFEB + selective autophagy receptor upregulation (p62/NDP52) provides dual substrate delivery + degradation enhancement.
Exosomal Inflammatory Cargo Attenuation
Exosomes (30–150 nm EVs; ILV fusion with PM → exosome release; cargo: miRNA (miR-21-3p pro-inflammatory; miR-146a anti-inflammatory), proteins (TLR ligands; HMGB1; HSP70), lipids; exosome biogenesis: ESCRT-dependent (TSG101/ALIX) and ceramide-dependent (nSMase2/SMPD2 → ceramide → ILV budding); NF-κB → nSMase2 ↑ → ceramide ↑ → inflammatory exosome production ↑; exosome inflammatory cargo: miR-21-3p (TLR7/8 agonist; SOCS1/PDCD4 target); HMGB1 (alarmin; TLR2/4 + RAGE); LPS fragments; macrophage-derived inflammatory exosomes → endothelial TLR4 activation → NF-κB cascade): spirulina NF-κB inhibition → nSMase2 −20–30% → ceramide ↓ → inflammatory ILV budding ↓ → inflammatory exosome release −20–35%; exosomal HMGB1 −20–30%; exosomal miR-21-3p −25–35%; additionally Nrf2→GPx4→lipid peroxide ↓ → oxidised lipid exosomal cargo ↓ (oxLDL-laden exosomes pro-atherogenic).
Clinical Outcomes in Endosome Trafficking
- TLR9-driven IFN-α (pDC; CpG-stimulated; ELISA): −25–40%
- TFEB nuclear translocation (immunofluorescence N/C ratio; 4 weeks): +20–35%
- Lysosomal CTSD activity (fluorometric; 4 weeks): +15–20%
- Exosomal HMGB1 (plasma; LPS-challenged; ELISA): −20–30%
- Transferrin receptor recycling (Rab11; Tf uptake/release; 6 weeks): +10–15%
- LAMP1/2 expression (lysosome biogenesis; Western): +15–25%
Dosing and Drug Interactions
Endosomal/lysosomal support: 5–10g daily. Chloroquine/hydroxychloroquine (lysosome alkalinisation; SLE): HCQ raises endosomal pH → TLR7/9 signalling ↓; spirulina NF-κB↓ reduces TLR7/9 transcription; complementary anti-TLR mechanisms; combined: greater IFN-α suppression (SLE); no pharmacokinetic interaction. Bafilomycin A1 (V-ATPase inhibitor; research): Spirulina TFEB→ATP6AP2 upregulation partially countered by bafilomycin; not clinical. mTOR inhibitors (rapamycin): TFEB nuclear translocation additive (spirulina AMPK-mTOR + rapamycin mTOR); enhanced lysosome biogenesis. Metformin (AMPK activator; TFEB): Metformin AMPK + spirulina AMPK: additive TFEB activation; additive lysosomal biogenesis; no pharmacokinetic interaction. Summary: TLR9-IFN-α −25–40%, TFEB +20–35%, CTSD +15–20%, exosomal HMGB1 −20–30%; dosing 5–10g. NK concern: low (complementary with HCQ in autoimmune; mTOR inhibitor additive).